In vitro Pharmacodynamics and PK/PD in Animals
- PMID: 31364074
- DOI: 10.1007/978-3-030-16373-0_8
In vitro Pharmacodynamics and PK/PD in Animals
Abstract
In the last decade, considerable advancements have been made to identify the pharmacokinetic/pharmacodynamic (PK/PD) index that defines the antimicrobial activity of polymyxins. Dose-fractionation studies performed in hollow-fiber models found that altering the dosing schedule had little impact on the killing or suppression of resistance emergence, alluding to AUC/MIC as the pharmacodynamic index that best describes polymyxin's activity. For in vivo efficacy, the PK/PD index that was the most predictive of the antibacterial effect of colistin against P. aeruginosa and A. baumannii was ƒAUC/MIC.
Keywords: In vitro; In vivo; Pharmacodynamics; Pharmacokinetics; Polymyxin.
Similar articles
-
Pharmacokinetics/Pharmacodynamics of Pulmonary Delivery of Colistin against Pseudomonas aeruginosa in a Mouse Lung Infection Model.Antimicrob Agents Chemother. 2017 Feb 23;61(3):e02025-16. doi: 10.1128/AAC.02025-16. Print 2017 Mar. Antimicrob Agents Chemother. 2017. PMID: 28031207 Free PMC article.
-
Performances of the Rapid Polymyxin Acinetobacter and Pseudomonas Tests for Colistin Susceptibility Testing.Microb Drug Resist. 2019 May;25(4):520-523. doi: 10.1089/mdr.2018.0153. Epub 2018 Dec 1. Microb Drug Resist. 2019. PMID: 30508392
-
fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models.J Antimicrob Chemother. 2010 Sep;65(9):1984-90. doi: 10.1093/jac/dkq226. Epub 2010 Jun 23. J Antimicrob Chemother. 2010. PMID: 20573659 Free PMC article.
-
Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?Diagn Microbiol Infect Dis. 2012 Nov;74(3):213-23. doi: 10.1016/j.diagmicrobio.2012.07.010. Epub 2012 Sep 6. Diagn Microbiol Infect Dis. 2012. PMID: 22959816 Free PMC article. Review.
-
Synergistic combinations of polymyxins.Int J Antimicrob Agents. 2016 Dec;48(6):607-613. doi: 10.1016/j.ijantimicag.2016.09.014. Epub 2016 Oct 24. Int J Antimicrob Agents. 2016. PMID: 27865626 Free PMC article. Review.
Cited by
-
Clinically Relevant Concentrations of Polymyxin B and Meropenem Synergistically Kill Multidrug-Resistant Pseudomonas aeruginosa and Minimize Biofilm Formation.Antibiotics (Basel). 2021 Apr 8;10(4):405. doi: 10.3390/antibiotics10040405. Antibiotics (Basel). 2021. PMID: 33918040 Free PMC article.
-
Pharmacokinetic/Pharmacodynamic Based Breakpoints of Polymyxin B for Bloodstream Infections Caused by Multidrug-Resistant Gram-Negative Pathogens.Front Pharmacol. 2022 Jan 4;12:785893. doi: 10.3389/fphar.2021.785893. eCollection 2021. Front Pharmacol. 2022. PMID: 35058776 Free PMC article.
-
Establishing Rationale for the Clinical Development of Cell Therapy Products: Consensus between Risk and Benefit.Int J Stem Cells. 2023 Feb 28;16(1):16-26. doi: 10.15283/ijsc21189. Epub 2022 Dec 31. Int J Stem Cells. 2023. PMID: 36581365 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical